Clinical Trial Update: Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating ROCK inhibitor fasudil as a disease-modifying treatment for amyotrophic lateral sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• fasudil (fasudil)

Snippet

Sponsor: University Medical Center Goettingen | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED